News

Most people with cystic fibrosis (CF) have fungi in their airways, but the fungi may come and go in waves of activity, a Spanish study suggests. The study, “Fungal microbiota dynamics and its geographical, age and gender variability in patients with cystic fibrosis,” was published in Clinical Microbiology…

Adults and children with cystic fibrosis (CF) frequently have moderate to severe gastrointestinal (GI) symptoms such as fullness and bloating, and women are primarily affected, new research suggests. GI-targeted medications were largely not effective and both age groups reported being highly dissatisfied with them. The study, “Multicentre prospective…

A new test that measures the excretion of bicarbonate in urine may be used to assess the effectiveness of treatments for cystic fibrosis (CF), according to a new study. “The goal is for the urine test to be used as a clinical tool to determine both the severity of…

Defects in both epithelial and immune cells contribute to changes in the gut microbiota, the populations of microbes naturally present in the gut, seen in cystic fibrosis (CF), a recent study in mice showed. While the immune component had the greater effect in the small intestine, however, the epithelial…

Blood levels of two hormones, kisspeptin and proopiomelanocortin, are lower in people with cystic fibrosis (CF) — beginning in childhood and continuing through adulthood — than in healthy people, a study found. These reduced concentrations may be associated with lower body weight, delayed puberty and poorer fertility in CF…

Twelve months into the COVID-19 pandemic, Australian adults and children with cystic fibrosis (CF) showed improved lung function and body mass index (BMI), as well as a lower hospitalization rate, a study reports. “Differing models of care and major changes in community interactions both have the…

Differences in levels of proteins related to wound healing, cell migration and neurological development may influence whether or not people with cystic fibrosis (CF) experience improved lung function with Kalydeco (ivacaftor), according to a new analysis. The analysis found that “differences in…

Treatment with the triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) reduces inflammation and promotes lung tissue repair in cystic fibrosis (CF), new research indicates. Nicola Robinson, MD, from The University of Edinburgh, presented the findings at the 2022 North American Cystic Fibrosis Conference, in the talk “Elexacaftor/Tezacaftor/Ivacaftor treatment promotes inflammation…

People with cystic fibrosis (CF) tend to report improvements in health-related quality of life associated with treatment with Trikafta. Reports of worse mental health were common, however, and were identified as an area of need. That’s according to data shared by Aricca Van Citters, from The Dartmouth Institute for Health Policy & Clinical Practice,…

Later this month, Laurent Pharmaceuticals will meet with the U.S. Food and Drug Administration (FDA) to discuss next steps for LAU-7b, the company’s experimental inflammation-controlling therapy for cystic fibrosis (CF) that showed promise in a recent Phase 2 study. “There was no precedent in cystic…